Urothelial Carcinoma Clinical Trials

43 studies are recruiting for urothelial carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

  1. A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

    This is a first-in-human (FIH), Phase 1 open-label, multicentre dose escalation study investigating AVA6000 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumours that are likely to be FAP positive. The study consists of an initial Phase …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    9 in total
    Run by
    Avacta Life Sciences Ltd
  2. Bladder Cancer Screening Trial

    There is currently no accepted screening strategy for patients at high risk of developing bladder cancer. This study will ask patients to complete a urine test every 6 months for 2 years to help assess if routine screening helps finding bladder cancer at an earlier stage.

    Stage
    Not phased
    Ages
    50 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center
  3. Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

    This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pat…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
    Run by
    University of California, Irvine
  4. Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

    The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults whose cancer failed conventional BCG therapy. The drugs are given directly into the bladder (intravesi…

    Stage
    Phase 2
    Ages
    18 to 99
    Site
    University of Iowa, Iowa City, Iowa
    Run by
    Michael A. O'Donnell
  5. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

    This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dana Farber Cancer Institute, Boston, Massachusetts
    Locations
    3 in total
    Run by
    Zumutor Biologics Inc.
  6. Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments

    The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its …

    Stage
    Not phased
    Ages
    65 and older
    Site
    Dana-Farber Cancer Institute, Boston, Massachusetts
    Run by
    Dana-Farber Cancer Institute
  7. Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

    Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op. Risk of post-op complications will be analyzed.

    Stage
    Not phased
    Ages
    18 to 85
    Site
    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
    Locations
    2 in total
    Run by
    Thomas Jefferson University
  8. Circulating Tumor DNA Response In Urothelial Cancer

    The purpose of this clinical trial is to evaluate the effectiveness of pembrolizumab monotherapy following 24 weeks of frontline pembrolizumab \& Enfortumab Vedotin (PEV) in patients with metastatic urothelial cancer (mUC).

    Stage
    Phase 2
    Ages
    18 and older
    Site
    OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
    Run by
    University of Oklahoma
  9. An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

    The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds norm…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center
  10. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Dren Investigational Site, Denver, Colorado
    Locations
    10 in total
    Run by
    Dren Bio
  11. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Southern California, Los Angeles, California
    Locations
    6 in total
    Run by
    Tanabe Pharma America, Inc.
  12. Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

    This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacod…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEXT Oncology, Fairfax, Virginia
    Run by
    LG Chem
  13. Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

    This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based cfDNA assay to predict the presence of residual tumor remaining in the bladder at cystectomy. Patients who are planned fo…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Nebraska Medical Center, Omaha, Nebraska
    Locations
    2 in total
    Run by
    Fox Chase Cancer Center
  14. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Birmingham, Alabama
    Locations
    68 in total
    Run by
    Massive Bio, Inc.
  15. Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Cancer

    Urothelial cancers of the bladder and upper urinary tract account for over 200,000 deaths and 600,000 diagnoses annually worldwide. The most common presenting symptom is hematuria (blood in urine), triggering a cascade of tests, including an invasive examination of the bladder using a flexible scop…

    Stage
    Not phased
    Ages
    18 to 100
    Site
    Vancouver Prostate Centre, Vancouver, British Columbia
    Locations
    8 in total
    Run by
    Tampere University Hospital
  16. Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

    The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell carcinoma. The main questions it aims to answer are: * To determine oncologic outcomes, specifically 2-year recurr…

    Stage
    Not phased
    Ages
    19 and older
    Site
    University of Florida Health Science Center, Gainesville, Florida
    Locations
    4 in total
    Run by
    Case Comprehensive Cancer Center
  17. A Multicenter Cancer Biospecimen Collection Study

    This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Curebase, San Francisco, California
    Run by
    Cofactor Genomics, Inc.
  18. uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

    The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Providence St. Johns Health Center, Santa Monica, California
    Locations
    22 in total
    Run by
    UroGen Pharma Ltd.

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.